Prognosis
Pfizer Submits Early Data on Boosters’ Protection to FDA
- Third dose led to higher levels of protective antibodies
- Companies seeking regular licensure instead of emergency use
This article is for subscribers only.
Pfizer Inc. and BioNTech SE submitted early-stage data to U.S. regulators showing that a third dose of their Covid-19 vaccine led to higher levels of protective antibodies when given eight to nine months after the initial regimen.
The companies expect results from a larger final-stage trial evaluating the effects of the third booster dose shortly, according to a statement Monday, which will be submitted to the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities.